B cells as therapeutic targets in autoimmune neurological disorders
- 23 September 2008
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Neurology
- Vol. 4 (10) , 557-567
- https://doi.org/10.1038/ncpneuro0901
Abstract
Nature Clinical Practice Neurology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.Keywords
This publication has 54 references indexed in Scilit:
- Duration of Humoral Immunity to Common Viral and Vaccine AntigensNew England Journal of Medicine, 2007
- A Proliferation‐inducing Ligand (APRIL) is Expressed by Astrocytes and is Increased in Multiple SclerosisScandinavian Journal of Immunology, 2006
- Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody productionSeminars in Immunology, 2006
- B cells move to centre stage: novel opportunities for autoimmune disease treatmentNature Reviews Drug Discovery, 2006
- Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple SclerosisNew England Journal of Medicine, 2005
- Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case reportThe Journal of Pediatrics, 2003
- Treatment of IgM antibody associated polyneuropathies using rituximabJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodiesMuscle & Nerve, 2003
- Receptor-Mediated Antigen Uptake and its Effect on Antigen Presentation to Class II-Restricted T LymphocytesAnnual Review of Immunology, 1990